Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 27, 2023
Reporting Period: Fiscal Year ended June 30, 2023
This filing serves as a notification that the Company issued a press release on September 27, 2023, announcing its financial results for the fiscal year ended June 30, 2023. The press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes or comparative financial data are disclosed within the text of this Form 8-K. The document solely announces the availability of the fiscal year results in a separate press release.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific guidance, outlook, management commentary, or risk factors are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated September 27, 2023) for actual revenue, profit, and cash flow figures for the fiscal year ended June 30, 2023.
- Verify the Company's liquidity position and debt levels in the full press release or subsequent 10-K filing.
- Confirm if the press release contains updated forward-looking guidance or material risk factors not present in this summary.